A top an­a­lyst sees Pfiz­er and Mod­er­na seiz­ing a $38B prize as safe­ty frets side­line glob­al vac­cine play­ers

5 years ago
Bioregnum
Coronavirus

Saman­tha Du's Zai Lab sets its am­bi­tions sky high, look­ing to raise $750M to fu­el its li­cens­ing busi­ness mod­el

5 years ago
Financing

No AAV? No prob­lem. Code Bio­ther­a­peu­tics joins the search for a non-vi­ral gene ther­a­py

5 years ago
Financing

FDA slaps a hold on KalVis­ta's PhII study of an HAE drug, rais­ing a red flag on pre­clin­i­cal re­sults

5 years ago
R&D
FDA+

Ver­tex pays CRISPR $900M to take con­trol of sick­le cell part­ner­ship, bet­ting they can beat blue­bird -- and re­new­ing ...

5 years ago
Deals

Covid-19 roundup: In­dia nudges US to lift ma­te­ri­als ex­port ban as cas­es surge

5 years ago
Coronavirus

Chen Yu jumps ship from Vi­vo Cap­i­tal and goes large, al­ly­ing with The Col­umn Group on an in­au­gur­al $824M biotech ...

5 years ago
Financing
China

Ja­mi Ru­bin, once fa­bled for grilling bio­phar­ma ex­ecs, de­camps to head fi­nance at drug pric­ing dis­rupter

5 years ago
People

Seagen gets Au­gust PDU­FA for Pad­cev ex­pan­sions; Adap­tate pulls in new cash for gam­ma delta T cell an­ti­bod­ies

5 years ago
News Briefing

The doc­tor is in: Trump in­sid­er Ben Car­son joins NASH play­er Galectin as a 'spe­cial con­sul­tant,' part-time spokesman

5 years ago
People

FDA lays the ham­mer on Emer­gen­t's Bal­ti­more plant af­ter J&J de­ba­cle, halt­ing all pro­duc­tion in un­usu­al move

5 years ago
R&D
Manufacturing

New Kaiser analy­sis shows how lim­it­ing price ne­go­ti­a­tions to tar­get­ed drugs may bet­ter fo­cus up­com­ing leg­is­la­tion

5 years ago
R&D
Pharma

Ovid cuts its loss­es on con­tro­ver­sial An­gel­man syn­drome drug, mak­ing its crush­ing de­vel­op­ment halt per­ma­nent

5 years ago
R&D

FDA slaps a hold on Mof­fitt’s next-gen CAR-T as reg­u­la­tors de­mand an­oth­er de­lay on clin­i­cal work — shares crater

5 years ago
R&D
FDA+

Covid-19 roundup: Sup­ply chain short­ages lead to half the Mod­er­na dos­es de­liv­ered to Cana­da; J&J shots paused out of ...

5 years ago
Coronavirus

Kazia swipes an ex-Sanofi mol­e­cule for £1M up­front as they look to repli­cate their Genen­tech snag

5 years ago
Deals

Till­man Gern­gross' Covid-19 an­ti­body moon­shot scores $336M with the help of new ace CFO. Is an IPO next?

5 years ago
Financing
Coronavirus

Biotech's IPO raise ap­proach­es $5.5B as Nas­daq con­tin­ues to prove fruit­ful with 2 de­buts and three new fil­ings

5 years ago
Financing

When is a drug re­al­ly a de­vice? Court knocks down FDA ap­peal in try­ing to sort that grey area

5 years ago
Pharma
FDA+

Q1: A flood of in­vestor cash drove biotech's num­bers to new record highs, and the tor­rent of cash is mov­ing up­stream ...

5 years ago
Deals

Re­cur­sion founders gin for­tunes as IPO back­ers show­er $436M on one of the biggest boasts in AI — based on some very ...

5 years ago
Bioregnum
Opinion

Covid-19 vac­cine halt drags on, an FDA ap­point­ment at long last, the great CRO con­sol­i­da­tion, and more

5 years ago
Weekly

TG Ther­a­peu­tics pre­pares to ap­proach reg­u­la­tors with MS drug; In­vestors bet $93M on a life sci­ences tools com­pa­ny

5 years ago
News Briefing

As­traZeneca-Alex­ion merg­er slides through FTC re­view af­ter sup­posed M&A crack­down pos­es no bar­ri­ers

5 years ago
Deals
Pharma
First page Previous page 715716717718719720721 Next page Last page
A service from the Financial Times